Tuesday, February 10, 2015

Measles/MMR Vaccine Can Cause Diabetes, Arthritis, Death

David Dees,
deesillustration.com

Is the “Cure” Worse Than the Disease?

As the “debate” ensues throughout the US concerning the recent measles outbreak among vaccinated children, some journalists and commentators are even suggesting that children be vaccinated against their parents’ will, or that parents reluctant to vaccinate their children be imprisoned.


A careful look at the research pharmaceutical companies are legally compelled to provide with vaccines may give parents pause. According to the insert accompanying the 2014 version of Merck Inc.’s Measles Mumps Rubella (MMR II) vaccine, the live viruses are “propagated in chick embryo cell culture” and “WI-38 human diploid lung fibroblasts.” (See full listing of vaccine inserts.)

Seldom do medical practitioners explain in sufficient detail the potential side effects of vaccines to parents, thus violating the simple and straightforward policy of informed consent. Nor do they remind parents that vaccine manufacturers have immunity from civil action in the event their infant or child is injured or killed from the vaccine.

Merck’s own research states that its MMR vaccine can cause the following: diabetes, vasculitis, pancreatitis, thrombocytopenia (inability for blood to clot), angioneurotic edema (non-inflammatory swelling of the skin), pneumonia, bronchial spasm, arthritis, optic neuritis (inflammation of the optic nerve), Guillain-Barré Syndrome, and death.

Merck’s MMR vaccine may also cancer and impact the child’s fertility in later years. “M-M-R II has not been evaluated for carcinogenic or mutagenic potential, or potential to impair fertility,” the vaccine’s insert reads. Limited research exists for most vaccines because longitudinal studies of vaccine recipients are difficult and costly to carry out.

Like most Americans conditioned for several decades now to distrust their own reasoning, those who become parents are similarly inclined to defer to scientific and institutional authority to make the decision to vaccinate their children. However, if mom and dad were thoroughly apprised of the potential for such side effects most would likely be far more tentative toward the administration of such foreign substances.

In fact, as is the case with many pharmaceutical products, in the broader scheme of things the symptoms of the illness may be preferable to the alleged “cure.”

According to the Centers for Disease Control, measles begins with high fever, cough, runny nose (coryza), and red, watery eyes (conjunctivitis). “Two or three days after symptoms begin,” the CDC notes, “tiny white spots (Koplik spots) may appear inside the mouth.” A few days after symptoms are observed
a rash breaks out. It usually begins as flat red spots that appear on the face at the hairline and spread downward to the neck, trunk, arms, legs, and feet. Small raised bumps may also appear on top of the flat red spots. The spots may become joined together as they spread from the head to the rest of the body. When the rash appears, a person’s fever may spike to more than 104° Fahrenheit.

After a few days, the fever subsides and the rash fades.
Following this ordeal the individual’s fully operational immune system will have had the opportunity to produce a formidable lifelong measles defense.

For comparative purposes below is a full description of the Merck’s MMR II vaccine’s potential side effects and consequences as described on its insert.

ADVERSE REACTIONS TO MMR II VACCINE

The following adverse reactions are listed in decreasing order of severity, without regard to causality, within each body system category and have been reported during clinical trials, with use of the marketed vaccine, or with use of monovalent or bivalent vaccine containing measles, mumps, or rubella:

Body as a Whole
Panniculitis; atypical measles; fever; syncope; headache; dizziness; malaise; irritability.

Cardiovascular System
Vasculitis.

Digestive System
Pancreatitis; diarrhea; vomiting; parotitis; nausea.

Endocrine System
Diabetes mellitus.

Hemic and Lymphatic System
Thrombocytopenia (see WARNINGS, Thrombocytopenia); purpura; regional lymphadenopathy; leukocytosis.

Immune System
Anaphylaxis and anaphylactoid reactions have been reported as well as related phenomena such as angioneurotic edema (including peripheral or facial edema) and bronchial spasm in individuals with or without an allergic history.

Musculoskeletal System
Arthritis; arthralgia; myalgia. Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children. This type of involvement as well as myalgia and paresthesia, have also been reported following administration of MERUVAX II.

Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms.

Following vaccination in children, reactions in join ts are uncommon and generally of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0-3%; women: 12-26%), {17,56,57} and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and in adult women. Even in women older than 35 years, these reactions are generally well tolerated and rarelyinterfere with normal activities.

Nervous System
Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS); subacutesclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia. Experience from more than 80 million doses of all live measles vaccines given in the U.S. through 1975 indicates that significant central nervous system reactions such as encephalitis and encephalopathy, occurring within 30 days after vaccination, have been temporally associated with measles vaccine very rarely.{58} In no case has it been shown that reactions were actually caused by vaccine. The Centers for Disease Control and Prevention has pointed out that “a certain number of cases of encephalitis may be expected to occur in a large childhood population in a defined period of time even when no vaccines are administered”. However, the data suggest the possibility that some of these cases may have been caused by measles vaccines. The risk of such serious neurological disorders following live measles virus vaccine administration remains far less than that for encephalitis and encephalopathy with wild-type measles (one per two thousand reported cases).

Post-marketing surveillance of the more than 200 million doses of M-M-R and M-M-R II that have been distributed worldwide over 25 years (1971 to 1996) indicates that serious adverse events such as encephalitis and encephalopathy continue to be rarely reported.{17} There have been reports of subacute sclerosing panenc ephalitis (SSPE) in children who did not have a history of infection with wild-type measles but did receive measles vaccine. Some of these cases may have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination.

Based on estimated nationwide measles vaccine distribution, the association of SSPE cases to measles vaccination is about one case per million vaccine doses distributed. This is far less than the association with infection with wild-type measles, 6-22 cases of SSPE per million cases of measles. The results of a retrospective case-controlled study conducted by the Centers for Disease Control and Prevention suggest that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its inherent higher risk of SSPE.{59}

Cases of aseptic meningitis have been reported to VAERS following measles, mumps, and rubella vaccination. Although a causal relationship between the Urabe strain of mumps vaccine and aseptic meningitis has been shown, there is no evidence to link Jeryl Lynn™ mumps vaccine to aseptic meningitis.

Respiratory System
Pneumonia; pneumonitis (see CONTRAINDICATIONS); sore throat; cough; rhinitis.

Skin
Stevens-Johnson syndrome; erythema multiforme; urticaria; rash; measles-like rash; pruritis. Local reactions including burning/stinging at injection site; wheal and flare; redness (erythema); swelling; induration; tenderness; vesiculation at injection site.

Special Senses — Ear Nerve
deafness; otitis media.

Special Senses — Eye
Retinitis; optic neuritis; papillitis; retrobulbar neuritis; conjunctivitis.

Urogenital System
Epididymitis; orchitis.

Other

Death from various, and in some cases unknown, causes has been reported rarely following vaccination with measles, mumps, and rubella vaccines; however, a causal relationship has not been established in healthy individuals (see CONTRAINDICATIONS).

No comments:

Post a Comment